| Name | Title | Contact Details |
|---|
Phoenix Flavors & Fragrances is a leading developer and manufacturer of customized flavors and fragrances, with over two decades of experience in the industry. The company is dedicated to delivering high-quality, artisanal products that help clients innovate and stay competitive. Phoenix collaborates closely with its customers to create bespoke solutions, ensuring that each product meets the highest standards of quality and performance. Based in New Jersey, Phoenix employs between 501 and 1000 people and has a strong regulatory team and advanced quality assurance laboratories. This enables the company to maintain compliance with industry regulations and adapt to changing consumer preferences. In 2022, Phoenix expanded its capabilities by acquiring Innovative Fragrances, enhancing its offerings in the home fragrance, personal care, candles, and air fresheners markets. The company serves a diverse range of brands across various sectors, including food, beverages, and personal care.
Mitsubishi Polyester Film is a leading supplier of polyester (PET) film, part of Mitsubishi Chemical America, Inc. The company operates manufacturing sites in the USA, Europe, Japan, Indonesia, and China, with a total global capacity of 250,000 tons. It specializes in biaxially oriented polyester (boPET) films, offering a range of thicknesses and polymer types for various applications. Key brands include Hostaphan® and Diafoil®. The company emphasizes vertical integration, with on-site PET resin manufacturing and over 50 coating types. It also focuses on sustainability through initiatives like the REPROCESS™ recycling program, which incorporates post-industrial recycled content. Mitsubishi Polyester Film provides customized solutions through its global R&D efforts, addressing product design, manufacturing, logistics, and process challenges.
Lockton Affinity is a division of Lockton Companies that focuses on underwriting and distributing specialty insurance products. It operates in markets that are outside the standard offerings, catering to unique insurance needs. Lockton Companies, the parent organization, is a global insurance brokerage known for its client-focused and family-owned approach.
Cabinetworks Group is a prominent manufacturer and distributor of kitchen and bath cabinets in the United States. As the largest privately held cabinetmaker in the country and the second-largest overall, the company boasts a diverse portfolio of cabinetry brands, including well-known names like KraftMaid, Medallion, Schuler, and Advanta. Their products cater to a wide range of consumers and price points, ensuring options for various needs. The company serves a broad customer base, including kitchen and bath showrooms, builders, architects, and specifiers for multi-family properties. With over 8,000 employees and 18 manufacturing facilities across 24 locations, Cabinetworks Group maintains a strong presence in the market. As a portfolio company of Platinum Equity, it is committed to growth and innovation in the cabinetry sector, while also offering various career opportunities and fostering a culture of community involvement.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.